Kane Biotech Inc. (KNE), a biotechnology company focused on microbial biofilm technologies, announced Thursday that it has received approval from the Internal Review Board (IRB) of the University of Miami Health System (UHealth) to commence a clinical trial for its DispersinB Acne Cleanser.
The trial will study the product's effectiveness in treating mild to moderate Acne Vulgaris.
The study, titled "Split-face efficacy and tolerability of DispersinB Acne Cleanser", will involve up to 24 subjects and is expected to begin by mid-2025 at the University of Miami Miller School of Medicine.
The Dr. Phillip Frost Department of Dermatology is recognized as a global leader in skin care.
This approval is a significant milestone for Kane Biotech as the company advances its mission to develop science-driven dermatological solutions, with DispersinB offering a groundbreaking approach to acne treatment.
Currently, KNBIF is trading at $0.07 up at 12.72%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.